Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27642890 | 1.00 | GABRR1 (0.46) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL469702 | 0.90 | CYP2D6 (0.41) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL29979714 | 0.90 | CYP2D6 (0.41) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL6872772 | 0.90 | CYP2D6 (0.41) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL6154559 | 0.87 | CYP2D6 (0.50) | CYP2D6HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL6873754 | 0.85 | GABRR1 (0.41) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL2368380 | 0.84 | CYP2D6 (0.42) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL23072790 | 0.82 | GABRR1 (0.42) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL14822743 | 0.82 | GABRR1 (0.38) | GABRR1LMNACYP2D6HDAC3HDAC1 | |
| SCHEMBL28825762 | 0.82 | CYP2D6 (0.44) | CYP2D6HDAC3HDAC1HDAC2HDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
| US-20050234082-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-10-20 | — | — | US | disclosed |
| US-6872728-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-03-29 | — | — | US | disclosed |
| US-20040048884-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-03-11 | — | — | US | disclosed |
| US-6608197-B2 | Aminoalkyl-substituted pyrimidones | NEUROCRINE BIOSCIENCES, INC. | 2003-08-19 | — | — | US | disclosed |
| US-20020132820-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2002-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234082-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GABRR1 175/4885LMNA 3749/4885CYP2D6 790/4885 |
| US-20020132820-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GABRR1 145/4885LMNA 4024/4885CYP2D6 572/4885 |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | HAVCR2, MAVS, CD4 | GABRR1 1640/4885LMNA 3518/4885CYP2D6 2283/4885 |
| US-20040048884-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GABRR1 145/4885LMNA 4024/4885CYP2D6 572/4885 |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CPSF6, NFATC1, CPSF1 | GABRR1 3421/4885LMNA 1295/4885CYP2D6 494/4885 |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | GABRR1 175/4885LMNA 3749/4885CYP2D6 790/4885 |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | CCR10, CCR1, CCR3 | GABRR1 316/4885LMNA 3767/4885CYP2D6 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.